The effects of Okra supplementation on blood pressure, lipid profile, and inflammation in patients with prediabetes, type 2 diabetes, and diabetic nephropathy: a meta-analysis and systematic review Authors: Ke Zhang, Yan Ma, Wenwen Lu, Xinhuan Zhang, Fujun Wang, Jing Liu Published: 2026 ABSTRACT Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Okra (Abelmoschus esculentus), a traditional plant rich in fiber, flavonoids, and antioxidants, has been suggested to improve glycemic control, lipid metabolism, and inflammation, but clinical evidence remains inconsistent. The major objective of our review was to elucidate the impact of okra supplementation on blood pressure, lipid profile, and inflammation in patients with prediabetes, T2DM, and diabetic nephropathy. Eligible studies were identified through PubMed, Embase, Web of Science, and Scopus up to February 17, 2026. Pooled weighted mean differences (WMD) with 95% confidence intervals (CI) were calculated using random-effects models. Ten studies were included. Okra supplementation significantly reduced total cholesterol (14.16 mg/dL, 95% CI: −22.39, −5.92, P < 0.001), LDL-C (−8.51 mg/dL, 95% CI: −14.92, −2.11, P = 0.009), triglycerides (−15.43 mg/dL, 95% CI: -28.67, -2.19, P = 0.022), diastolic blood pressure (–1.17 mmHg; 95% CI: –2.28 to –0.06), and CRP (–2.28 mg/dL; 95% CI: –2.70 to –1.86). No significant effects were observed for systolic blood pressure or HDL-C overall. Okra supplementation exerts beneficial effects on lipid profiles, diastolic blood pressure, and systemic inflammation in individuals with prediabetes, T2DM, and diabetic nephropathy, suggesting a potential role as an adjunctive therapy for reducing CVD risk. Introduction Type 2 diabetes mellitus (T2DM) is associated with numerous cardiovascular complications and significantly increases the risk of mortality and heart-related diseases [1]. Cardiovascular diseases (CVDs) are linked to various risk elements such as systolic blood pressure (SBP), low-density lipoprotein cholesterol (LDL-C), body mass index (BMI), and fasting blood glucose (FBG) [2]. Individuals with type 2 diabetes have a two-fold enhanced CVD risk in comparison to those who do not have type 2 diabetes [3]. Hence, the risk of CVD should be minimized in individuals with type 2 diabetes. Although various medicines are available for the treatment of type 2 diabetes, these medications are often associated with adverse effects [4]. In addition to concerns about side effects, natural treatments are often preferred due to their affordability and accessibility, particularly in low-resource settings where conventional medications may be costly or less available [5]. Locally available plants such as okra provide a culturally acceptable and sustainable option for patients seeking complementary therapies for T2DM. This warrants the use of natural treatments for diabetes with fewer adverse effects Lifestyle modifications and diet serve a crucial function in managing type 2 diabetes [6]. Diet is recommended as the first-line management strategy for CVD [7]. Alternative treatments, such as herbal plants with antioxidant properties, help reduce stress and control diabetes [8–10]. One such natural traditional plant is okra, which has antioxidant activity [11]. Okra, from the Malvaceae family, contains flavonoids that contribute to its antioxidant effects [12]. Okra also contains soluble fiber, including gums and pectin, and other vital nutrients. Soluble fibers are successful in lowering cholesterol concentrations in the serum and reducing CVD risk [13]. Okra not only contains soluble and insoluble fiber but is also a rich source of vitamins (A, C, K, and several B-complex vitamins such as folate) and minerals (including calcium, magnesium, potassium, and iron), in addition to carbohydrates, thereby providing significant health benefits for humans [14]. Previous studies have confirmed the positive impacts of okra on type 2 diabetes, CVD, and cancer [15]. A systematic review reported that okra had a positive impact on hyperlipidemia and hyperglycemia due to its antioxidant effect [16]. A pre-clinical study demonstrated that okra achieves a lipid-lowering effect and could thus be used as a cardiovascular-friendly vegetable [17]. Okra consumption, regardless of exercise training, resulted in a cardioprotective effect in rats [18]. A double-blind randomized controlled trial (RCT) confirmed that okra consumption was effective in improving the lipid profile and FBG concentration among T2DM patients [19]. However, the authors emphasized the need for larger, longer-duration trials with diverse populations to confirm these findings and establish the long-term safety of okra supplementation. Previous meta-analysis exists on similar topics [20, 21]. While the prior studies focused on the effect of okra on dyslipidemia and hyperglycemia in pre-diabetic and T2DM patients, our study provides a novel contribution by assessing the effects of okra on the CVD risk factors, including blood pressure, lipid profile, and inflammation in patients with prediabetes, T2DM, and diabetic nephropathy. Within the broader context of other nutraceutical interventions targeting similar outcomes, a recent meta-analysis found that cinnamon supplementation significantly improved lipid profiles, blood pressure, and CRP levels in adults [22]. A low-fructose diet has been shown to significantly reduce SBP and triglyceride (TG) levels [23]. However, given the absence of systematic reviews and meta-analyses of RCTs on the effect of okra on CVD risk factors in patients with prediabetes, T2DM, and diabetic nephropathy, this meta-analysis has been performed. As far as we are aware, this is the initial meta-analysis aimed at clarifying the evidence from RCTs summarizing the effect of okra on CVD risk factors in diabetic patients. The primary aim of our review was to elucidate the impact of okra supplementation regarding blood pressure, lipid profile, and inflammation in patients with prediabetes, T2DM, and diabetic nephropathy. Materials and Methods Systematic review and meta-analysis framework This study utilized a systematic review combined with meta-analysis to assess the effects of okra supplementation on blood pressure, lipid profiles, and C-reactive protein (CRP) levels in individuals with T2DM. The research methodology was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework to ensure methodological rigor and transparency. Although this review was not prospectively registered in PROSPERO, all procedures strictly adhered to PRISMA standards, employing predefined eligibility criteria and analytical strategies to reduce potential bias and strengthen the reliability of the findings [24]. Search strategy A comprehensive literature search was conducted across multiple electronic databases, including Embase, Scopus, Web of Science, PubMed/Medline and Google scholar for studies available until February 17, 2026. The search strategy incorporated a blend of Medical Subject Heading (MeSH) and non-MeSH keywords: (“Okra” OR “Abelmoschus esculentus”) AND (“Randomized controlled study” OR “Clinical Trials” OR “Intervention Studies” OR “intervention” OR “controlled trial” OR “trial” OR “randomized” OR “placebo” OR “random” OR “assignment”) (see Supplementary Table 1). Additionally, we searched trial registries, including ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform, to identify ongoing or unpublished studies. Reference lists of relevant systematic reviews were also manually screened to capture any studies that may have been missed during the database and registry searches. Grey literature sources such as dissertations and conference proceedings were not included, as our focus was on peer-reviewed studies to ensure methodological rigor and reliability of the findings. Inclusion criteria The inclusion criteria were defined based on the PICOS framework: Population (P): Adults aged 18 years or older with prediabetes, T2DM, and diabetic nephropathy; Intervention (I): Okra supplementation; Comparison (C): Control group without okra supplementation or a placebo; Outcomes (O): Changes in CRP, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), LDL-C, TG, SBP, and diastolic blood pressure (DBP); Study design (S): Original research employing an RCT design and reporting pre- and post-intervention data for both intervention and control groups or changes in the measured outcomes. Exclusion criteria Studies were not included if they met any of the following criteria: (1) Conducted on animal models or in vitro settings; (2) Lacked sufficient data at either baseline or post-intervention time points; (3) Did not follow an RCT design.; (4) Assessed okra supplementation in conjunction with other interventions (co-supplementation studies); and (5) Consisted of unpublished sources, including dissertations, conference abstracts, and patents. Data extraction Relevant data from each selected study were systematically extracted by two independent researchers (K.Z and Y.M). Any discrepancies that arose were resolved through discussion with a third researcher (J.L). To assess consistency between reviewers, we calculated Cohen’s kappa statistic, which indicated excellent agreement (κ = 0.87). Extracted information included study location, participant demographics (age, gender), first author’s name, baseline and post-intervention outcome measures (mean and standard deviation), trial duration, year of publication, participant health status, okra dosage, study design, and sample size. Quality assessment The methodological quality of the included studies was assessed using the Cochrane Risk of Bias 2 (ROB2) tool, which examined potential biases in randomization, intervention adherence, missing data, outcome measurement, selective reporting, and overall study integrity [25]. Each study was classified as having a low risk, some concerns, or a high risk of bias. Furthermore, the certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework, which categorized it as very low, low, moderate, or high [26]. Data synthesis and statistical analysis All statistical analyses were performed using Stata version 15 (StataCorp, College Station, Texas, USA), with a significance threshold of p < 0.05. Random-effects meta-analyses were conducted using the metan command. Heterogeneity was assessed using the metan output (I² and Tau² statistics). Publication bias was evaluated using funnel plots generated with metafunnel and statistically tested using metabias (Egger’s and Begg’s tests). The trim-and-fill method was implemented using the metatrim command. Sensitivity analyses were conducted using leave-one-out analysis via the metaninf command. The statistical code used for the primary analyses is provided in Appendix 1 to enhance reproducibility. The impact of okra supplementation was assessed by calculating the mean changes and standard deviations (SD) of the measured variables from baseline to post-intervention. Effect sizes were determined using weighted mean differences (WMD) with corresponding 95% confidence intervals (CI). A random-effects model was applied to account for potential variations across studies [27, 28]. When outcome measures were reported in different formats, standard formulas were used to harmonize data. In cases where SDs for net changes were not explicitly provided, they were estimated using the formula: SD change = √[(SDpre)² + (SDpost)² - (2 × R × SDpre × SDpost)], where R is the assumed correlation coefficient between pre- and post-intervention measures. A correlation coefficient of 0.5 was assumed, as recommended in previous methodological studies [29, 30]. When outcomes were reported in different measurement units across studies, values were converted to a common unit prior to pooling. Lipid parameters (TC, LDL-C, HDL-C) reported in mmol/L were converted to mg/dL using a factor of 38.67. Triglyceride values were converted using a factor of 88.57 (1 mmol/L = 88.57 mg/dL). For glucose-related variables, when applicable, a conversion factor of 18 was used (1 mmol/L = 18 mg/dL). CRP concentrations reported in mg/L were converted to mg/dL where necessary (1 mg/dL = 10 mg/L) to ensure consistency across studies. Blood pressure outcomes were uniformly reported in mmHg and required no conversion. Heterogeneity among studies was quantified using the I² statistic, where values exceeding 50% and p-values below 0.1 were indicative of moderate to substantial heterogeneity [31]. To assess the robustness of the findings, sensitivity analyses were conducted by systematically excluding individual studies to observe their impact on the pooled effect size [29]. Subgroup analyses were conducted based on intervention dose, duration, baseline BMI, baseline FBS, baseline lipid value, age, and country, where sufficient data were available. Potential publication bias was examined using funnel plot visualization, with Begg’s and Egger’s tests applied to statistically assess asymmetry. In cases where publication bias was detected, the ‘trim and fill’ method was used to correct for any potentially missing studies[32]. Results Study selection The process of literature selection is detailed in Fig. 1. Initially, 1,086 records were identified through databases (PubMed (n = 121), Scopus (n = 761), Web of sciences (n = 109), Embase databases (n = 213), and Google scholar (n = 2)). After removing 443 duplicate entries, 746 articles were excluded based on title and abstract screening. Of these, six were excluded for not meeting the inclusion criteria: three involved co-supplementation with other components [33–35], one lacked a control group [36], and two did not provide sufficient outcome data [37, 38], resulting in 10 articles being deemed suitable for the final quantitative analysis [19, 39–47]. Although the inclusion criteria specified RCTs, Haryati et al. (2019), a quasi-experimental study, was included due to the limited number of RCTs examining okra supplementation in diabetic populations. The study satisfied all other PICOS elements, including the target population, intervention, comparator, and relevant outcome measures. To address potential bias, sensitivity analyses were conducted with and without this study to evaluate its impact on the overall findings. Two independent researchers conducted the study screening and data extraction processes. To assess consistency between researchers, we calculated Cohen’s kappa statistic, which indicated excellent agreement (κ = 0.87).Fig. 1Flow chart of study selection and inclusion in the meta-analysis.The diagram illustrates the process of literature identification, screening, eligibility assessment, and final inclusion of studies according to predefined criteria. Numbers at each stage indicate the records identified, excluded, and included in the quantitative synthesis. Flow chart of study selection and inclusion in the meta-analysis. The diagram illustrates the process of literature identification, screening, eligibility assessment, and final inclusion of studies according to predefined criteria. Numbers at each stage indicate the records identified, excluded, and included in the quantitative synthesis. Characteristics of the included studies A summary of the eight eligible studies is provided in Table 1. The study populations comprised individuals with type 2 diabetes and prediabetic subjects. The participants in these trials had an average age between 40.8 and 62 years, with both male and female individuals included in the studies. Baseline BMI values spanned from 24.9 to 30.34 kg/m². The included studies, published between 2019 and 2025, were conducted in Iran, China, and Indonesia. Okra supplementation regimens varied in duration from 2 weeks to 3 months, with dosages ranging between 3 and 20 grams per day. According to the GRADE assessment, the certainty of evidence supporting reductions in TC, LDL-C, TG, DBP, and CRP with okra supplementation was rated as moderate, primarily downgraded due to inconsistency across studies. The certainty of evidence for SBP and HDL-C was rated as low, reflecting high heterogeneity and imprecision in effect estimates (Supplementary Table 2). The methodological quality and risk of bias assessment of these trials are detailed in Supplementary Table 3.Table 1Characteristics of eligible studies.Author, yearCountryPopulationParticipants age(year)Baseline BMISample sizeAstaxanthin /PlaceboDurationOkra dosageOutcomesRaiesifar, A.(2025)IranType 2 diabetic patients51.53nr30/3028 daysParticipants consumed four okra fruits in manufactured paper glasses with a 50 cc capacity, placing the four okras in 30 cc of water (kept in a refrigerator at a temperature of 8 to 16 °C) for 24 h.TC, HDL-C, LDL-C, TGHesamzadeh, Ali, (2025)IranType 2 diabetic patients53.4129.9627/2660 days3000 mg of okraTGNikpayam, O., (2024)IranPatients with diabetic nephropathy6230.3530/2510week125 mg (4 g of okra)CRPBahreini, N.,(2024)IranPatients with diabetic nephropathy6230.3530/2510week125 mg (4 g of okra)TC, HDL-C, LDL-C, TG, SBP, DBPAfsharmanesh, Mohammad Reza, (2024)IranPre-diabetic Adults45.81nr35/358 weeks3000 mg of okraTC, HDL-C, LDL-C, TGTavakolizadeh, M., (2023)IranType 2 diabetic patients53.828.648/463 months3000 powdered okra fruitTC, HDL-C, LDL-C, TG, SBP, DBP, CRPChen, Lin, (2023)ChinaPatients with Impaired glucose tolerance (IGT)40.8nr30/3060 days20 g of dried H. esculentus fruit teaTC, HDL-C, LDL-C, TGSaatchi, A., (2022)IranPatients with diabetes type 257.730.250/508 weeks4,000 mg/day of OkraTC, HDL-C, LDL-C, TG, SBP, DBPMoradi, A., (2020)IranType 2 diabetic adults54.2624.925/238 weeks10 g okraTC, HDL-C, LDL-C, TG, SBP, DBPHaryati, (2019)IndonesiaType 2 Diabetes Mellitusnrnr15/152 weeksThree pieces of fresh okra fruit in 250 ml waterTC, FBS Table 1Characteristics of eligible studies.Author, yearCountryPopulationParticipants age(year)Baseline BMISample sizeAstaxanthin /PlaceboDurationOkra dosageOutcomesRaiesifar, A.(2025)IranType 2 diabetic patients51.53nr30/3028 daysParticipants consumed four okra fruits in manufactured paper glasses with a 50 cc capacity, placing the four okras in 30 cc of water (kept in a refrigerator at a temperature of 8 to 16 °C) for 24 h.TC, HDL-C, LDL-C, TGHesamzadeh, Ali, (2025)IranType 2 diabetic patients53.4129.9627/2660 days3000 mg of okraTGNikpayam, O., (2024)IranPatients with diabetic nephropathy6230.3530/2510week125 mg (4 g of okra)CRPBahreini, N.,(2024)IranPatients with diabetic nephropathy6230.3530/2510week125 mg (4 g of okra)TC, HDL-C, LDL-C, TG, SBP, DBPAfsharmanesh, Mohammad Reza, (2024)IranPre-diabetic Adults45.81nr35/358 weeks3000 mg of okraTC, HDL-C, LDL-C, TGTavakolizadeh, M., (2023)IranType 2 diabetic patients53.828.648/463 months3000 powdered okra fruitTC, HDL-C, LDL-C, TG, SBP, DBP, CRPChen, Lin, (2023)ChinaPatients with Impaired glucose tolerance (IGT)40.8nr30/3060 days20 g of dried H. esculentus fruit teaTC, HDL-C, LDL-C, TGSaatchi, A., (2022)IranPatients with diabetes type 257.730.250/508 weeks4,000 mg/day of OkraTC, HDL-C, LDL-C, TG, SBP, DBPMoradi, A., (2020)IranType 2 diabetic adults54.2624.925/238 weeks10 g okraTC, HDL-C, LDL-C, TG, SBP, DBPHaryati, (2019)IndonesiaType 2 Diabetes Mellitusnrnr15/152 weeksThree pieces of fresh okra fruit in 250 ml waterTC, FBS Characteristics of eligible studies. Findings from the Meta-analysis Effect of Okra Supplementation on Total Cholesterol (TC) Data on TC levels were extracted from 8 studies, encompassing a total of 517 participants (263 in the okra group and 254 in the control group). The pooled results revealed a statistically significant reduction in TC following okra consumption (WMD: −14.16 mg/dL, 95% CI: −22.39, −5.92, P < 0.001), with substantial heterogeneity among arms (I² = 96.2%, 95% CI: 58-98.7%, P < 0.001; Tau²=120.36) (Fig. 2). Subgroup analyses revealed consistent reductions in TC across multiple subgroups (Supplementary Table 4). Trials administering ≤ 4 g/day of okra showed a larger decrease in TC (WMD: –14.95 mg/dL; 95% CI: –20.29, –9.62), whereas doses >4 g/day produced did not produce significant changes. Interventions > 2 months demonstrated greater improvements (WMD: –16.53 mg/dL; 95% CI: –27.12, –5.94) compared with interventions lasting ≤ 2 months (WMD: –12.88 mg/dL; 95% CI: –23.98, –1.79). TC reductions were observed in both age groups ( < 60 and ≥ 60 years), although heterogeneity remained substantial. TC improvements were also similar across BMI categories and baseline FBS levels. Country-specific analyses indicated significant reductions in Iranian studies, while studies from China and Indonesia reported non-significant effects (Suppl. Fig. 1).Fig. 2Effect of okra supplementation on total cholesterol (TC).Forest plot showing the weighted mean differences (WMDs) and 95% confidence intervals (CIs) for TC between intervention and control groups in randomized controlled trials. Squares represent individual study effect sizes, horizontal lines indicate 95% CIs, and the diamond represents the pooled effect estimate. Effect of okra supplementation on total cholesterol (TC). Forest plot showing the weighted mean differences (WMDs) and 95% confidence intervals (CIs) for TC between intervention and control groups in randomized controlled trials. Squares represent individual study effect sizes, horizontal lines indicate 95% CIs, and the diamond represents the pooled effect estimate. Effect of Okra supplementation on HDL-C HDL-C data from 7 studies, including 487 participants (248 okra, 239 placebo), revealed no significant changes in HDL-C concentrations post-intervention (WMD: 2.95 mg/dL, 95% CI: -0.39, 6.30, P = 0.066), though study heterogeneity was high (I² = 99.1%, 95% CI: 0.0- 99.5%, P < 0.001; Tau² = 19.34) (Fig. 3). Subgroup analysis demonstrated that while the overall pooled estimate for HDL-C was non-significant, interventions longer than 2 months produced a significant increase (WMD: 1.56 mg/dL; 95% CI: 1.22, 1.91) (Supplementary Table 4). Neither dose subgroup showed significant improvements. Participants aged ≥60 years experienced increases in HDL-C, though only one study contributed data. Individuals with baseline FBS < 125 mg/dL demonstrated marked increases (WMD: 2.92 mg/dL; 95% CI: 0.82, 5.02), whereas those with higher baseline FBS did not. HDL-C did not significantly change in subgroups stratified by BMI or baseline HDL-C levels. Geographic subgrouping showed significant increases only in Iranian trials (Supplementary Fig. 1).Fig. 3Effect of okra supplementation on high-density lipoprotein cholesterol (HDL-C).Forest plot showing the weighted mean differences (WMDs) and 95% confidence intervals (CIs) for HDL-C between intervention and control groups. Squares represent individual studies, horizontal lines indicate 95% CIs, and the diamond represents the pooled effect size. Effect of okra supplementation on high-density lipoprotein cholesterol (HDL-C). Forest plot showing the weighted mean differences (WMDs) and 95% confidence intervals (CIs) for HDL-C between intervention and control groups. Squares represent individual studies, horizontal lines indicate 95% CIs, and the diamond represents the pooled effect size. Effect of Okra supplementation on LDL-C LDL-C data from 6 trials (487 participants) demonstrated a significant reduction following okra supplementation (WMD: -8.51 mg/dL, 95% CI: −14.92, −2.11, P = 0.009) with considerable heterogeneity (I² = 96.1%, 95% CI: 75.1–98.5%, P < 0.001; Tau²=71) (Fig. 4). LDL-C decreased across several subgroups, with greater improvements observed in trials using ≤4 g/day of okra (WMD: –8.20 mg/dL; 95% CI: –14.52, –1.86) compared with higher doses (WMD: –8.78 mg/dL; 95% CI: –22.62, 5.04) (Supplementary Table 4). Longer intervention duration ( > 2 months) consistently yielded larger LDL-C reductions (WMD: –9.76 mg/dL; 95% CI: –17.08, –2.44). LDL-C decreased in both age groups ( < 60 and ≥ 60 years). Participants with BMI < 30 kg/m² exhibited larger reductions than those with BMI ≥ 30. Both strata of baseline FBS showed non-significant pooled estimates, though the direction of effect favored okra. The effect was significant in Iranian studies, whereas the Chinese study showed no change.Fig. 4Effect of okra supplementation on low-density lipoprotein cholesterol (LDL-C).Forest plot presenting weighted mean differences (WMDs) and 95% confidence intervals (CIs) for LDL-C. Squares indicate study-specific estimates, horizontal lines represent 95% CIs, and the diamond indicates the overall pooled effect. Effect of okra supplementation on low-density lipoprotein cholesterol (LDL-C). Forest plot presenting weighted mean differences (WMDs) and 95% confidence intervals (CIs) for LDL-C. Squares indicate study-specific estimates, horizontal lines represent 95% CIs, and the diamond indicates the overall pooled effect. Effect of Okra supplementation on Triglyceride (TG) TG levels from 8 studies (540 participants) indicated a significant reduction after okra supplementation (WMD: −15.43 mg/dL, 95% CI: −28.67, −2.19, P = 0.022), with substantial heterogeneity among arms (I² = 75.3%, 95% CI: 0.0-91.1%, P < 0.001; Tau²=223.57) (Fig. 5). Subgroup analysis showed that TG reductions were more pronounced in trials lasting > 2 months (WMD: –19.25 mg/dL; 95% CI: –22.02, –14.84), whereas shorter interventions did not produce significant changes (Supplementary Table 4).Fig. 5Effect of okra supplementation on triglycerides (TG).Forest plot showing weighted mean differences (WMDs) and 95% confidence intervals (CIs) for TG across included randomized controlled trials. Squares represent individual study estimates, horizontal lines show 95% CIs, and the diamond represents the pooled estimate. Effect of okra supplementation on triglycerides (TG). Forest plot showing weighted mean differences (WMDs) and 95% confidence intervals (CIs) for TG across included randomized controlled trials. Squares represent individual study estimates, horizontal lines show 95% CIs, and the diamond represents the pooled estimate. TG decreased across several subgroups, with significant improvements observed in trials using >4 g/day of okra (WMD: –25.39 mg/dL; 95% CI: -45.40, –5.39) compared with ≤4 g/day doses (WMD: –11.15 mg/dL; 95% CI: –23.35, 1.04). Larger reductions were observed among participants aged ≥60 years (WMD: –20.00 mg/dL; 95% CI: –31.31, –8.68), while younger participants showed no significant effect. Individuals with baseline TG ≥ 150 mg/dL experienced meaningful decreases (WMD: –17.67 mg/dL; 95% CI: –25.70, –9.63), in contrast to those with baseline TG < 150 mg/dL, who exhibited an increase. Similar to TC, TG reductions were significant in Iranian trials but not in the study conducted in China (Supplementary Fig. 1). Effect of Okra supplementation on Systolic Blood Pressure (SBP) SBP data from 4 studies (297 participants) showed no significant changes following okra supplementation (WMD: −1.49 mmHg, 95% CI: −5.28, 2.29, P = 0.439), with notable heterogeneity among arms (I² = 96%, 95% CI: 0.0-99%, P < 0.001; Tau²=14) (Fig. 6). Across subgroups, okra supplementation did not significantly reduce SBP(Supplementary Table 4). Neither dose category ( ≤ 4 g/day or >4 g/day) showed meaningful changes. Interventions longer than 2 months also failed to produce significant effects. Participants aged ≥60 years demonstrated a notable reduction in SBP (WMD: –8.02 mmHg; 95% CI: –10.13, –5.91), although this finding was based on a single study. No significant effects were observed across BMI categories. Substantial heterogeneity persisted in most subgroup analyses, suggesting variability in study design or population characteristics (Supplementary Fig. 1).Fig. 6Effect of okra supplementation on systolic and diastolic blood pressure.A Forest plot showing the weighted mean differences (WMDs) and 95% confidence intervals (CIs) for systolic blood pressure (SBP). B Forest plot showing the weighted mean differences (WMDs) and 95% confidence intervals (CIs) for diastolic blood pressure (DBP). Squares indicate individual study effects, horizontal lines represent 95% CIs, and diamonds indicate pooled estimates. Effect of okra supplementation on systolic and diastolic blood pressure. A Forest plot showing the weighted mean differences (WMDs) and 95% confidence intervals (CIs) for systolic blood pressure (SBP). B Forest plot showing the weighted mean differences (WMDs) and 95% confidence intervals (CIs) for diastolic blood pressure (DBP). Squares indicate individual study effects, horizontal lines represent 95% CIs, and diamonds indicate pooled estimates. Effect of Okra Supplementation on Diastolic Blood Pressure (DBP) DBP data from 4 studies (297 participants) indicated a significant reduction after okra intake (WMD: −1.17 mmHg, 95% CI: −2.28, −0.06, P = 0.038), with moderate heterogeneity (I² = 49%, 95% CI: 0.0-84.5%, P = 0.116; Tau² = 0.60) (Fig. 6). Subgroup analysis identified reductions in DBP among participants aged ≥ 60 years (WMD: –2.31 mmHg; 95% CI: –3.84, –0.79), whereas younger participants showed only borderline effects (Supplementary Table 4). Dose and duration did not substantially modify the overall effect, as both ≤ 2-month and > 2-month trials reported small but non-significant changes. Participants with BMI ≥ 30 kg/m² experienced significant reductions (WMD: –2.19 mmHg; 95% CI: –3.46, –0.91). No significant effects were observed in other BMI or FBS strata (Supplementary Fig. 1). Effect of Okra supplementation on C-reactive Protein (CRP) CRP data from 2 studies (297 participants) showed a significant reduction following okra supplementation (WMD: −2.28 mg/dL, 95% CI: −2.70, −1.86, P < 0.001), with no detected heterogeneity (I² = 0.0%, 95% CI: 0.0–66.6%, P = 0.440; Tau² = 0.0.00). Subgroup analyses were not available for CRP because only two studies reported data. Both studies consistently demonstrated significant decreases in CRP with minimal heterogeneity, indicating a robust anti-inflammatory effect irrespective of participant characteristics. Sensitivity analysis No single study significantly influenced the overall pooled effect sizes in the meta-analysis (Supplementary Fig. 2). Publication bias Evaluation through funnel plots and Egger’s regression test found no signs of publication bias in the meta-analysis assessing the effects of okra supplementation on the outcomes studied. The trim and fill analysis did not identify any potentially missing studies, indicating no significant publication bias (Fig. 7). The trim and fill analysis for TG detected some unpublished article ans results was changed to (n = 13, WMD: −34.61 mg/dL, 95% CI: −46.20, −23.01, P < 0.001). TC detected some unpublished article and results was changed to (n = 12, WMD: −23.49 mg/dL, 95% CI: −30.94, −16.04, P < 0.001).Fig. 7Assessment of publication bias using a funnel plot.A Systolic blood pressure (SBP), B diastolic blood pressure (DBP), C total cholesterol (TC), D high-density lipoprotein cholesterol (HDL-C), E low-density lipoprotein cholesterol (LDL-C), and F triglycerides (TG). Funnel plot of weighted mean differences (WMDs) against their standard errors (SEs). Each point represents an individual study. Symmetry around the pooled effect estimate suggests a lower likelihood of publication bias. The x-axis shows the effect size (WMD), and the y-axis represents the standard error of the effect size. The diagonal lines indicate the pseudo 95% confidence limits. P values correspond to Egger’s test for publication bias. Assessment of publication bias using a funnel plot. A Systolic blood pressure (SBP), B diastolic blood pressure (DBP), C total cholesterol (TC), D high-density lipoprotein cholesterol (HDL-C), E low-density lipoprotein cholesterol (LDL-C), and F triglycerides (TG). Funnel plot of weighted mean differences (WMDs) against their standard errors (SEs). Each point represents an individual study. Symmetry around the pooled effect estimate suggests a lower likelihood of publication bias. The x-axis shows the effect size (WMD), and the y-axis represents the standard error of the effect size. The diagonal lines indicate the pseudo 95% confidence limits. P values correspond to Egger’s test for publication bias. Discussion The present meta-analysis of RCT assessed the effectiveness of okra on lipid profile (TC, HDL-C, LDL-C, and TG), blood pressure, and CRP in individuals with type 2 diabetes. The findings indicated that okra considerably reduced DBP, TC, TG, LDL-C, and CRP; however, there was no notable impact on SBP and HDL-C. From a clinical perspective, the magnitude of lipid reductions observed in this meta-analysis may be modest but potentially meaningful. A reduction of approximately 8–15 mg/dL in LDL-C and TC, if sustained long term, could translate into incremental reductions in cardiovascular risk, particularly in high-risk populations such as individuals with type 2 diabetes. Similarly, the observed reduction in CRP suggests attenuation of systemic inflammation, a key contributor to atherosclerosis progression. In contrast, the reduction in DBP (–1.17 mmHg) was small, and although statistically significant, its independent clinical impact is likely limited unless combined with broader lifestyle or pharmacologic interventions. Therefore, okra supplementation should be viewed as a complementary strategy rather than a replacement for established therapies. Findings from the subgroup analysis disclosed that the significant impact of okra on TC, TG, and LDL-C were more predominant with an okra dosage not exceeding 4 g/day and lasting for more than 2 months. Even the rise in the levels of HDL-C was significant in RCT with a duration of > 2 months in the subgroup analysis. These results suggest that even a low dosage of okra may exert a clinically relevant but modest effect on lipid profiles, underlining the effectiveness of okra in attenuating CVD risk. Importantly, subgroup analyses suggested that intervention duration may be a more consistent modifier of response than dosage. Trials lasting longer than 2 months demonstrated more pronounced improvements in TC, LDL-C, TG, and HDL-C compared with shorter interventions, indicating that sustained supplementation may be necessary to achieve meaningful metabolic effects. While lower doses ( ≤ 4 g/day) appeared effective for TC and LDL-C, higher doses ( > 4 g/day) were associated with greater reductions in TG, suggesting that the dose–response relationship may differ across lipid fractions. However, these subgroup findings should be interpreted cautiously, as formal meta-regression was not performed and the number of trials within each subgroup was limited. Compared to other plant-based nutraceuticals such as Nigella sativa, which has demonstrated significant improvements in lipid profiles, blood pressure, and inflammatory markers across 82 RCTs [48], the efficacy of okra appears promising though possibly more modest in magnitude. While Nigella sativa’s bioactive compound thymoquinone is a potent anti-inflammatory and lipid-lowering agent, okra exerts its effects through a broader spectrum of compounds, including flavonoids, polysaccharides, and fiber. These differences may result in distinct clinical applications or synergistic effects when used in combination. Although different management strategies are available for type 2 diabetes, it continues to be one of the most common chronic illnesses. Herbal therapies can be used as an adjuvant therapy for type 2 diabetes, and our meta-analysis proved that okra improved TC, LDL-C, TG, DBP, and CRP in type 2 diabetes individuals. In accordance with our results, another study concluded that 30 g per kg body weight of okra resulted in reduced TG and TC levels [49]. Another study demonstrated that okra favorably improved lipid levels due to its isoquercitrin, quercetin 3-O-gentiobioside, and flavonoids [50]. Okra binds with bile acid, inhibits the reabsorption of bile acid, decreases the biosynthesis of liver cholesterol, and thus reduces lipid peroxidation [51]. While the precise pathophysiology of the relationship between dyslipidemia and diabetes is not well understood, research has depicted the association between resistance to insulin and the abnormal lipoprotein metabolism [52]. Henceforth, free fatty acid influx exists in both serum and liver. When there is enough glycogen reserve in the liver, production of very low-density lipoprotein cholesterol (VLDL-C) is enhanced. The synthesis of VLDL-C is not reduced because of insulin resistance. Moreover, the inhibited effect of the enzyme lipoprotein lipase reduces the metabolic process and excretion of VLDL-C [53]. Research involving animals have reported the favorable impact of okra on lipid profiles and hypertension [54, 55]. Okra possesses high levels of quercetin-3-O-gentiobioside and isoquercitrin, which are accountable for reducing pancreatic lipase [56]. Regulation of peroxisome proliferator-activated receptor gamma may also be responsible for okra’s effect on lipids [16]. Polyphenols serve a significant purpose in the management of hyperlipidemia, due to their effect as peroxisome proliferator-activated receptor gamma ligand agonists [57]. Peroxisome proliferator-activated receptor gamma ligand agonists diminish the deposit of TG in the liver and thus demonstrate favorable efficacy on dyslipidemia [58]. Okra contains flavonoids, tannins, polyphenols, alkaloids, and steroids. Tannin coats the intestinal wall and attaches to body proteins, diminishing the absorption of fat [15]. The mechanism connecting dyslipidemia and CVD is oxidative stress related to reactive oxygen species and inflammation [59]. A systematic review of preclinical studies concluded that okra has the potential to lower CRP [60]. Several bioactive constituents in okra, particularly flavonoids, polyphenols, and polysaccharides, have demonstrated anti-inflammatory properties in both in vitro and in vivo studies. These compounds are thought to reduce systemic inflammation through several mechanisms: (a) inhibition of pro-inflammatory cytokines, (b) modulation of the NF-κB signaling pathway, (c) antioxidant activity, and (d) improved glycemic control and lipid profile (Fig. 8). These anti-inflammatory and metabolic-modulating effects suggest that okra may help reduce CRP levels and thereby contribute to lowering cardiovascular risk [61].Fig. 8Proposed mechanisms underlying the cardiometabolic effects of okra supplementation in diabetes.Schematic illustration summarizing the potential biological pathways through which okra supplementation may improve cardiometabolic outcomes, including modulation of glucose metabolism, lipid profile, oxidative stress, inflammation, insulin sensitivity, and blood pressure regulation. Arrows indicate proposed mechanistic relationships. Proposed mechanisms underlying the cardiometabolic effects of okra supplementation in diabetes. Schematic illustration summarizing the potential biological pathways through which okra supplementation may improve cardiometabolic outcomes, including modulation of glucose metabolism, lipid profile, oxidative stress, inflammation, insulin sensitivity, and blood pressure regulation. Arrows indicate proposed mechanistic relationships. Our results showed that DBP was significantly reduced following okra administration. This antihypertensive effect may be attributed to okra seed protein hydroxylates, which have been reported to modulate blood pressure regulation and could therefore play a role in managing hypertension [62]. Hypertension is a well-established risk factor for CVD, and improvements in blood pressure can contribute to overall cardiovascular risk reduction. Okra contains several bioactive compounds that are believed to contribute to its antihypertensive activity. These include flavonoids and polyphenols (exhibiting antioxidant and vasodilatory effects), polysaccharides and soluble fibers (modulating lipid metabolism and glucose levels, indirectly reducing blood pressure), okra seed protein hydrolysates (possessing angiotensin-converting enzyme (ACE) inhibitory activity), potassium content (known to help counteract sodium-induced hypertension). These mechanisms suggest that okra may act as a natural hypotensive agent through a combination of antioxidant, anti-inflammatory, ACE-inhibitory, and metabolic regulatory effects [63, 64]. Beyond its effect on blood pressure, okra also demonstrated beneficial impacts on other CVD-related markers, including lipid profile, CRP, and serum glucose levels. These changes may be interrelated, as the alleviation of inflammatory processes and improved glycemic control are known to positively influence cardiovascular outcomes [65]. Furthermore, okra has been shown to favorably alter fatty acid composition, reduce the atherogenicity of LDL-C, and decrease TG levels and oxidative vulnerability [39]. Notably, substantial heterogeneity was observed across several lipid outcomes (I² values exceeding 75% in most analyses). This variability may be attributable to differences in okra formulation (powder, extract, or seed-based preparations), dosage (3–20 g/day), intervention duration (2 weeks to 3 months), baseline metabolic status, BMI, and geographic location. The stronger effects observed in Iranian trials compared with studies conducted in China and Indonesia may reflect variations in dietary background, study design, or participant characteristics. Although subgroup analyses explored some of these variables, the limited number of trials restricted the ability to conduct robust meta-regression analyses to formally identify sources of heterogeneity. Therefore, pooled estimates should be interpreted with appropriate caution. Clinical implications The present findings suggest that okra supplementation may serve as a complementary dietary approach for improving lipid profiles and reducing systemic inflammation in individuals with type 2 diabetes or prediabetes. However, given the modest magnitude of effect and the observed heterogeneity, okra should not replace evidence-based pharmacotherapy but may be considered as an adjunct to lifestyle modification and medical treatment. Clinicians should also be aware of variability in formulation, dosage, and patient characteristics when considering its use. Future directions Future randomized controlled trials should employ standardized and chemically characterized okra preparations to reduce variability across studies. Larger, multicenter trials with longer follow-up durations are needed to evaluate dose–response relationships using formal meta-regression approaches and to determine whether improvements in surrogate markers translate into reductions in hard cardiovascular outcomes such as myocardial infarction, stroke, or mortality. Inclusion of non-Asian populations would improve generalizability, and systematic reporting of adverse events is essential to establish long-term safety. Strengths and limitations This review offers an up-to-date and comprehensive meta-analysis of randomized controlled trials examining the effects of okra supplementation on various cardiovascular risk factors, including lipid profiles, blood pressure, and markers of inflammation in individuals with T2DM, prediabetes, and diabetic nephropathy. A key strength of this study is its inclusion of the most recent evidence available up to 2025, alongside a broader range of outcomes compared to previous reviews. Nonetheless, several limitations should be acknowledged. Considerable heterogeneity was observed across all measured outcomes, including LDL-C, TG, HDL-C, TC, CRP, DBP, and SBP. The relatively small number of included studies and limited sample sizes restricted the ability to perform meaningful subgroup analyses or meta-regressions, thereby limiting the exploration of heterogeneity sources, particularly for outcomes with I² values exceeding 80%. We did not evaluate the effects of individual active compounds in okra, and confounding factors such as diet, physical activity, and lifestyle habits may have influenced the results of the included trials. Additionally, some studies involved participants with diabetic nephropathy, a microvascular complication of T2DM. While these findings are relevant, they should be interpreted within the context of diabetes-related complications rather than generalized to all individuals with T2DM. The inclusion of nephropathy-specific trials was intended to capture outcomes across the broader spectrum of T2DM without equating diabetic nephropathy and T2DM. Publication bias was assessed using funnel plots and Egger’s test; however, these approaches have limited reliability when the number of studies is small, due to low statistical power, and their results should therefore be interpreted cautiously. Furthermore, this review was not prospectively registered, which may reduce transparency. Another limitation is that all included studies were conducted exclusively in Asian populations, restricting the applicability of the results to other regions. This meta-analysis extends previous research, including the recent GRADE-assessed review [66], by providing a more targeted assessment of okra’s effects on cardiovascular risk factors. Although publication bias was not statistically detected, the small number of studies for certain outcomes (particularly CRP and blood pressure) limits the reliability of funnel plot asymmetry tests and Egger’s regression. Small-study effects cannot be entirely excluded, as trials with limited sample sizes may overestimate treatment effects. Additionally, some included studies presented concerns regarding allocation concealment or blinding, which may introduce performance or detection bias. The inclusion of a quasi-experimental study, although evaluated through sensitivity analysis, may also contribute to residual bias. Finally, the lack of prospective protocol registration may reduce methodological transparency and increase the possibility of selective reporting. Conclusion The present meta-analysis suggests that consumption of okra improves blood pressure, lipid profiles, and CRP in type 2 diabetes individuals and can reduce CVD risk, hence okra may be considered as a potentially beneficial adjunctive dietary strategy in type 2 diabetes patients. Nonetheless, additional effort is required to study the adverse effects of okra and its interactions with other foods and medications. Supplementary information Supplementary Figure 1 Appendix 1 Supplementary Figure 2 Supplementary Table 1 Supplementary Table 2 Supplementary Table 3 Supplementary Table 4 Supplementary Figure 1 Appendix 1 Supplementary Figure 2 Supplementary Table 1 Supplementary Table 2 Supplementary Table 3 Supplementary Table 4